![]() | ![]() |
Formats:
|
||||||||
NMDA-induced Seizure Intensity is Enhanced in COX-2 Deficient Mice 1Molecular Neuroscience Unit, Brain Physiology and Metabolism Section, National Institute on Aging, National Institutes of Health, Bethesda, MD 20892 2A. B. Hancock, Jr. Memorial Laboratory for Cancer Research, Departments of Biochemistry, Chemistry, and Pharmacology, Vanderbilt Institute of Chemical Biology, and Center in Molecular Toxicology, Vanderbilt University School of Medicine, Nashville, Tennessee 37232 Corresponding Author: Dr. Francesca Bosetti, Molecular Neuroscience Unit, Brain Physiology and Metabolism Section, National Institute on Aging, National Institutes of Health, 9 Memorial Drive, Room 1S126 MSC 0947, Bethesda, MD 20892, Phone: 301-594-5077, Fax: 301-402-0074, E-mail: frances/at/mail.nih.gov The publisher's final edited version of this article is available at Neurotoxicology.Abstract Pharmacological inhibition or genetic deletion of cyclooxygenase (COX)-2, but not COX-1, has been shown to increase susceptibility to kainic acid (KA)-induced excitotoxicity. However, it is unclear if susceptibility to excitotoxins that act through other neurotransmitter receptors is altered by COX-2 inhibition. To further understand the involvement of COX-2 in regulating susceptibility to excitotoxicity, we investigated the effect of COX-2 deletion on excitotoxicity induced by peripheral injection of N-methyl-D-aspartate (NMDA, a specific agonist of the NMDA receptors) or lindane (a GABAA receptor antagonist). COX-2−/− mice injected intraperitoneally with NMDA (50-100 mg/kg) exhibited significantly increased median seizure intensity when compared to COX-2+/+ mice. Further, COX-2−/− mice exposed to NMDA showed neuronal damage, detected by Fluoro Jade B (FJB) staining, in the CA3 region of the hippocampus. There was no FJB staining nor any significant difference in median or maximal seizure intensity in COX-2+/+ and COX-2−/− mice exposed to lindane. LC-MS/MS analysis of brain prostaglandin profile in COX-2−/− mice demonstrated a significant increase in PGF2α, TXB2, PGE2 and PGD2 expression 1 hour after administration of an excitotoxic dose of KA, but not of NMDA. Our findings demonstrate that COX-2 regulates susceptibility to KA and NMDA excitotoxicity, which directly activate glutamatergic neurotransmission, but not to lindane, which indirectly alters glutamatergic neurotransmission. Furthermore, increased levels of prostaglandins after seizures are associated with consistent manifestation of neuronal damage. Keywords: N-methyl-D-Aspartate, Prostaglandin, Excitotoxicity, Lindane, Kainate, Fluoro Jade B 1. Introduction Cyclooxygenase (COX) catalyzes the primary step in the metabolism of unesterified arachidonic acid to bioactive prostaglandins (PG) and thromboxanes (TX) (Smith et al. 2000). This metabolic pathway has been shown to play an important role both in physiological processes, such as synaptic transmission, neurotransmitter release and cerebral blood flow regulation as well as in neurological and neurodegenerative diseases, such as stroke, epilepsy, and Alzheimer's disease (Kam and See 2000; Katori and Majima 2000). Recent data suggest that while the COX isoforms, COX-1 and COX-2, catalyze the same metabolic reaction of arachidonic acid to PGH2, they may play differential roles in neuroinflammation and excitotoxicity (Bosetti 2007), a persistent overstimulation of excitatory neurotransmitter receptors that results in neuronal damage. Specifically, progression of the neuroinflammatory response to intracerebroventricular injections of lipopolysaccharide is dampened in mice deficient in COX-1 (Choi et al. 2008) and heightened in mice deficient in COX-2 (Aid et al. 2008). Furthermore, we have recently demonstrated that mice in which COX-2 was genetically deleted or chronically inhibited by celecoxib, expressed augmented kainic acid (KA)-induced excitotoxicity (Toscano et al. 2008). However, COX-1 deficient mice were not differentially susceptible to KA-induced excitotoxicity when compared to their wild-type counterparts. While this and other studies reporting an increased susceptibility to excitotoxicity when COX-2 is inhibited pharmacologically (Baik et al. 1999; Kim et al. 2008) suggest that deletion or inhibition of COX-2, but not COX-1, in the brain would result in increased susceptibility to all excitotoxicants, this has not been systematically tested. Therefore, in this study, we attempted to further our understanding of the role of the COX isoforms in excitotoxicity by examining the susceptibility of mice deficient in COX-2 (COX-2−/−) to N-methyl-D-aspartate (NMDA) and lindane, excitoxicants which act at sites distinctly different from those used in previous studies (Collingridge and Singer 1990; Narahashi 2002). NMDA is a methylated aspartate and a specific agonist of the NMDA receptor (NMDAR), one of the three types of ionotropic glutamate receptors expressed in the brain (Collingridge and Singer 1990). Exposure to either KA or NMDA results in the generation of limbic seizures which progress to neuronal damage in the cerebral cortex, hippocampus and other limbic structures in the brain (Wang et al. 2005). The exact mechanism of this excitotoxic neuronal damage has not been completely characterized but a prevailing theory suggests that the over excitation of the neurons allows significant concentrations of intracellular calcium to build, resulting in activation of calcium dependent proteases (Sattler and Tymianski 2001). Lindane, a persistent organic pollutant, exerts its seizurigenic activity in both experimental animals and humans (Telch and Jarvis 1982; Gilbert and Mack 1995) through its ability to antagonize the GABAA receptor (GABAR) and thereby disinhibit the central nervous system (Narahashi 2002). The removal of this inhibitory influence of GABA results in hyperexcitation of excitatory neurotransmitter receptors which may progress to seizures and excitotoxicity. Activation of the arachidonic acid metabolic pathway is known to occur after exposure to NMDA, KA and lindane (Kroll et al. 1999; Kawaguchi et al. 2005; Takemiya et al. 2006). The production of the bioactive eicosanoids from this process increases stimulation of their cognate receptors which mediate the downstream biological responses (Wright et al. 2001). While previous studies have shown increased production of individual prostaglandins in models of excitotoxicity (Kawaguchi et al. 2005; Takemiya et al. 2006), comprehensive analysis of the prostaglandin profile in the brains of mice after exposure to excitotoxins is lacking. Underlining the need for further understanding of mouse brain prostaglandin profile production in excitotoxicity is the observation that differential roles for the COX isoforms have been shown in the production of brain prostaglandins in response to KA in rats (Yoshikawa et al. 2006). Since we have recently established a role for COX-2 in modulating susceptibility to KA-induced excitotoxicity, it is important to understand how decreased activity of this isoform alters the mouse brain prostaglandin profile. With our recent demonstration that COX-2 deficient mice exhibit decreased spontaneous inhibitory postsynaptic currents in their CA1 pyramidal neurons along with increased susceptibility to KA-induced excitotoxicity (Toscano et al. 2008), we hypothesized that these mice would also have augmented NMDA and lindane-induced excitotoxicity. In this study, we demonstrate for the first time that COX-2 deficient mice exhibit augmented excitotoxicity to NMDA, but not to lindane. Furthermore, we also demonstrate that altered brain prostaglandin levels in COX-2 deficient mice correlate with neuronal damage. 2. Materials and Methods 2.1 Animal Procedures All procedures were performed under an approved animal protocol (NICHD #06-001) in accordance with NIH guidelines on the care and use of laboratory animals. Male COX-2 −/− and COX-2 +/+ mice used in this study had identical strain and genetic backgrounds and were obtained from heterozygous by heterozygous breedings, as detailed elsewhere (Toscano et al. 2007; Toscano et al. 2008). Mice were received at our facility at 6-8 weeks of age and were fed and watered ad libitum and maintained on a 12/12 light dark cycle. Mice (12-14 week-old) were injected intraperitoneally (i.p., injection volume 100-300 μl) with 10 mg/kg KA (Biomol International, Plymouth Meeting, PA; 2 mg/ml in 0.9% saline), 25-100 mg/kg N-methyl-D-aspartate (NMDA, Sigma, St. Louis, MO; 7.5-20 mg/ml in 0.9% saline) or 20-80 mg/kg lindane (γ-hexachlorocylohexane, Sigma; 4-16 mg/ml in corn oil) and then videotaped for 1 h after injection. Seizure intensity was rated using a modified Racine seizure scale for KA and NMDA and the Gilbert seizure scale for lindane (Gilbert and Mack 1995; Schauwecker and Steward 1997; Toscano et al. 2008). Two different seizure ratings scales were used due to the difference in molecular mechanism and in seizure manifestation between the compounds. KA and NMDA cause seizures by directly stimulating the glutamatergic system whereas lindane-induced seizures are due to inhibition of GABA receptors. Therefore, the manifestations of seizures for the two classes of compounds are distinctly different. Specifically, the Racine scale used in this study was 0 = no behavioral alteration; 1 = immobility, mouth and facial movements, facial clonus; 2= head nodding, forelimb and/or tail extension, rigid posture; 3= forelimb clonus, repetitive movements; 4= rearing, forelimb clonus with rearing, rearing and falling; 5= continuous rearing and falling, jumping; 6= severe tonic-clonic seizures. The Gilbert scale used in this study was: 0=no behavioral alteration; 1= jaw clonus, immobility, chewing in absence of boli or bedding, twitching of eyes and ears; 2= myoclonic jerk (MCJ), abrupt flexion or extension of forelimbs, head or neck; 3= multiple MCJ, more than 2 over the observation period; 4= prolonged MCJ, accompanied by rapid burst of chewing, forelimb clonus; 5= clonic seizures, uni- or bilateral forelimb clonus enduring for more than 10 seconds; 6=multiple clonic bouts, more than one clonic seizure episode over the observation period. Mice were assigned a seizure score (SS) for each 5 min interval over the course of the 1 h session, after which a median and a maximum SS was calculated for the entire 1 h session for each mouse. Mice were euthanized by decapitation 1 hour after injection with the test substances (for prostaglandin (PG) analysis) or 24 hours after injection with the test substances by intracardial perfusion with 4% paraformaldehyde (for histology) followed by overnight fixation of the brain in 4% paraformaldehyde and subsequent cryoprotection in 30% sucrose (Choi et al. 2008). 2.2 Fluoro Jade B Histology Cryoprotected mouse brains were sectioned coronally (30 μm) on a cryostat (Bright Instrument Company, LTD; Huntingdon, England) and stored at -20°C in antifreeze (30% glycerol, 30% ethylene glycol in 20 mM phosphate buffer at pH 7.2). Before use, sections were briefly rinsed in distilled water and then mounted on gelatin-coated glass specimen slides on which they were allowed to dry overnight. Fluoro Jade B (FJB) (Histo-Chem, Inc., Jefferson, AR) staining was performed as described previously (Schmued and Hopkins 2000; Toscano et al. 2008). Briefly, FJB is a histological stain which detects neuronal damage by staining neurons undergoing necrosis or apoptosis a fluorescent green color. Brain sections from positive (COX-2 −/− mice euthanized 24 hours after i.p. injection with 10 mg/kg KA) and negative (COX-2 −/− mice euthanized 24 hours after injection with 0.9% saline) controls were included in each batch of staining. Cresyl violet was performed as previously described (Toscano et al. 2008). 2.3 PG analysis by LC/MS/MS Mice were euthanized 1 h after injection with 10 mg/kg KA or 50 mg/kg NMDA by decapitation followed by rapid excision of the brain from the skull. Brains were snap frozen in methylbutane (Sigma) precooled with dry ice. LC-MS/MS analysis of whole brain prostaglandins was performed in a manner similar to that described previously (Kingsley et al. 2005). However, here the prostaglandins were detected by the mass spectrometer in negative ion mode. Brain samples were removed from -80C storage and immediately homogenized in a 1:5 solution of methanol:ethyl acetate with 0.5% acetic acid (v:v:v). Tetra-deuterated internal standards for PGF2α, PGE2, PGD2, Thromboxane B2 (TXB2) and 6-keto-PGF1α (Cayman Chemical, Ann Arbor, MI) were added to the homogenization vessel prior to homogenization. The homogenate was centrifuged and a portion of the supernatant was removed, evaporated to dryness under N2 and reconstituted in 300 μL methanol followed by 3 mL of aqueous 0.5% acetic acid. The reconstituted samples were then loaded onto OASIS HLB solid phase extraction cartridges (3cc 60mg, Waters Corp. Milford, MA) which had been pre-conditioned with 3 mL methanol followed by 3 mL 0.5% acetic acid(aq). The cartridges were washed with 3 mL 0.5% acetic acid(aq) followed by 3 mL 0.5% acetic acid(aq) with 15% methanol. After drying the sorbent bed for 2-3 minutes, the analytes were eluted with 3 mL of acetonitrile. The samples were dried under N2 and reconstituted in 50 μL methanol plus 75 μL H2O. Some reconstituted samples were opaque due to suspended particulate, thus all samples were filtered through 0.22 μm nylon filters. Finally, the samples were injected onto an LC-MS-MS system for analysis. The LC-MS-MS consisted of a Thermo Surveyor pump and autosampler in-line with a Thermo Quantum triple quadrupole mass spectrometer (Thermo Corp., Waltham, MA). Chromatographic separation was achieved on a C18 column (5.0 × 0.2 cm, 3 μm, Phenomenex, Torrance, CA) via gradient elution. Component B was increased from 25% to 50% over 3.5 minutes and held at 50% for an additional minute. Component B was acetonitrile with 0.5% acetic acid (v:v) while component A was H2O with 0.5% acetic acid (v:v). Analytes were detected by selected reaction monitoring (SRM) in the negative ion mode. The addition of acetic acid to the mobile phase, which was done to improve chromatographic peak shape, allows a robust response from prostaglandins in negative ion mode. Quantitation was achieved via stable isotope dilution. The analytes were detected with the following reactions (the mass in parentheses represents the mass of the deuterated internal standard): PGF2α(m/z 353(357)∧193(197)); PGE2 & PGD2 (m/z 351(355)∧271(275)); TXB2 (m/z 369(373)∧169(173)) and 6-keto-PGF1α (m/z 369(373)∧163(167)). 2.4 Statistics Mann-Whitney U-test (OpenStat 4; http://www.statpages.org/miller/openstat) was used for statistical analysis of seizure intensity due to their nature as ordinal measures. Seizure data are expressed as frequency or median and all other data are expressed as mean ± SD. Seizure data from all animals, whether they survived the observation period or not, were used to calculate median and maximal seizure intensity. Results from LC-MS/MS analysis of prostaglandins were analyzed with F test for homogeneity of variance and then, depending on the results of the F test, an unpaired t-test assuming equal variance or an unpaired t-test assuming unequal variance was calculated. p values <0.05 were considered statistically significant. 3. Results 3.1 NMDA-induced excitotoxicity is enhanced in COX-2 −/− mice COX-2 −/− mice injected with 50, 60 or 100 mg/kg NMDA had significantly enhanced median and maximum seizure intensity, assessed by Racine Seizure Scale (RSS) scores (Figure 1A
3.2 Lindane-induced seizure intensity is not affected by COX-2 deletion Although lindane-induced seizures did occur in both COX-2 +/+ and COX-2 −/− mice during the 1 hour period after injection, no difference in median (z=0.14, p=0.44; z=0.0001, p=0.50; z=0.87, p=0.19, respectively; n= 4-5/group) or maximal (z=0.2887, p=0.38; z=0.57; p=0.28; z=0.22, p=0.41, respectively; n=4-5/group) seizure intensity was observed at 20, 60 or 80 mg/kg. Furthermore, lindane-induced mortality occurred in a dose dependent fashion (20 mg/kg= 0%, 60 mg/kg = 20%, 80 mg/kg = 50%) and mortality rates were identical in COX-2+/+ and COX-2−/− mice. Additionally, no FJB positive neurons were observed in COX-2+/+ or COX-2−/− mice twenty-four hours after injection with 20, 60 or 80 mg/kg lindane. Since a non-lethal dose which caused differential seizure intensity in COX-2 +/+ and COX-2 −/− mice could not be identified and no FJB staining was observed at any dose tested, we concluded that COX-2 deficiency was not a significant determinant of lindane-induced excitotoxicity severity. 3.3 Prostaglandin levels are increased in the brains of COX-2 −/− mice in response to KA but not NMDA-induced seizures COX-2 −/− mice exhibited increased median seizure intensity in response to 50 mg/kg NMDA (COX-2 +/+ median= 1, COX-2 −/− median = 3; Fig 2A
Prostaglandin levels in the brains of mice injected with NMDA or KA were assessed by LC-MS/MS at 1 hour after injection. In COX-2 −/− mice injected with 10 mg/kg KA, brain levels of PGF2α, TXB2, PGE2 and PGD2 were all significantly elevated (Figure 2B 4. Discussion In this study, we have supported our previous findings that COX-2 −/− mice are more vulnerable to KA-induced excitotoxicity (Toscano et al. 2008) and further characterized the susceptibility of COX-2 −/− mice to excitotoxicity by describing an increase in seizure intensity induced by the glutamatergic agonist, NMDA (Figure 1 While it is not completely understood why lindane did not enhance seizure intensity in COX-2 −/− mice, it is possible that their increased susceptibly to excitotoxicity is only unmasked upon direct stimulation of the glutamatergic system. Since lindane evokes seizures through indirect stimulation of the glutamatergic system via disinhibition of the GABAA receptor and is less potent than other antagonists such as pentylenetetrazole (Tusell et al. 1992; Narahashi 2002), the magnitude of the disinhibition of the glutamatergic system may not have been sufficient, upon lindane exposure, for the mechanism of increased seizure susceptibility to be unmasked in the COX-2 −/− mice. Unfortunately, our ability to expand the dose range for lindane in our experiments was limited by significant mortality in groups exposed to the highest level of lindane used in this study. An emerging explanation of the role of COX-2 in exacerbation of seizures and mediation of neuronal damage due to brain insult involves the possibility that COX-2 plays a role in regulating neuronal activity since its inhibition before the introduction of a seizurigenic stimulus results in exacerbation of the seizure intensity (Gong et al. 2008; Toscano et al. 2008). However, it has also been suggested that COX-2 mediates the production of neuronal damage and inflammation in the brain since its inhibition after an insult to the brain seems to reduce subsequent neuronal damage (Gobbo and O'Mara 2004). When considering the latter point, it is important to remember that COX itself does not produce the final bioactive product or biological response but it is the downstream synthases and PG receptors, respectively, which perform these functions. Our data suggests that while deletion of COX-2 has profound and important effects on the intensity of seizure that manifests due to an excitotoxic stimulus (Toscano et al. 2008), it also suggests that the prostaglandin production and the subsequent stimulation of PG receptors is associated with manifestation of neuronal damage, a concept consistent with the results of similar experiments (Kim et al. 2008). It is unclear from our study whether the increased production of PGs in response to KA but not NMDA in COX-2 −/− is due to a release of the mediators from neurons as a chemical marker of damage (Pepicelli et al. 2002) or if the excitotoxic process stimulates the release of PGs from an alternative cellular compartment, such as glia (Tham et al. 2007). Therefore, we are unable to determine if the increase in PG production in our study plays a causative role in the neuronal damage observed 24 h after injection of KA, but not NMDA, or if they are strictly biomarkers of effect. What is clear from our study is that the prostaglandin profile produced during seizures does not influence the severity of the seizure since KA and NMDA injected COX-2 −/− mice exhibited identical median seizure intensity but very different quantities of PG production (Figure 2 The fact that significantly increased levels of prostaglandins were detected in COX-2−/− mice that demonstrated increased neuronal damage at 24 hours has several important implications. First, this observation suggests that COX-1 alone and through coupling with specific terminal synthases can produce prostaglandins in the brain. However, this does not suggest that the isoforms are physiologically equivalent since differential sensitivity to both seizure intensity and neuroinflammation have been demonstrated in mice lacking one or the other cyclooxygenase isoform (Bosetti et al. 2008; Choi et al. 2008; Toscano et al. 2008). Second, increased levels of prostaglandins correlate with the occurrence of neuronal damage in KA-induced excitotoxic effects. While slight differences in the total amounts of specific prostaglandin species produced in the brains of rats exposed to KA in a study by Yoshikawa et al and the brains of mice exposed to KA in our study may exist ((Yoshikawa et al. 2006); Figure 2B While it is uncertain at this point why KA exposure but not NMDA results in increased FJB staining (Toscano et al. 2008) and PG production in the presence of similar levels of seizure exacerbation in COX-2 −/− mice, our observations support the concept that seizure intensity may not be predictive of the extent of neuronal damage in models of excitotoxicity (Benkovic et al. 2004). However, it is possible that a variable other than seizure intensity, such as prostaglandin production or distinct stimulation of specific combinations of PG receptors, may be a better predictor of neuronal damage. If true, this would further emphasize the importance of eicosanoid metabolism and its physiological responses that occur downstream of the initial metabolic step of COX metabolism of arachidonic acid. Overall, our observations in this study further support the emerging body of data that suggests a role for COX-2 in regulating neuronal activity (Gong et al. 2008; Toscano et al. 2008). Furthermore, these observations continue to underscore the need for an epidemiological investigation to examine if the chronic usage of COX-2 selective inhibitors, poses an increased risk of seizure in susceptible populations, such as epileptics. Acknowledgments The authors would like to thank Dr. Robert Langenbach for supplying the cyclooxygenase-2 knockout mice and Drs. Saba Aid and Sang-Ho Choi for their helpful discussions and technical advice. This research was supported by the Intramural Research Program of the NIH, National Institute on Aging (Z01AG000423-04; CDT, FB) and by NIH grant # GM15431 to Dr. Lawrence Marnett. References
|
PubMed related articles
Your browsing activity is empty. Activity recording is turned off. |
|||||||
Annu Rev Biochem. 2000; 69():145-82.
[Annu Rev Biochem. 2000]Anaesthesia. 2000 May; 55(5):442-9.
[Anaesthesia. 2000]Inflamm Res. 2000 Aug; 49(8):367-92.
[Inflamm Res. 2000]J Neurochem. 2007 Aug; 102(3):577-86.
[J Neurochem. 2007]FASEB J. 2008 May; 22(5):1491-501.
[FASEB J. 2008]Trends Pharmacol Sci. 1990 Jul; 11(7):290-6.
[Trends Pharmacol Sci. 1990]Mol Neurobiol. 2005; 31(1-3):3-16.
[Mol Neurobiol. 2005]Mol Neurobiol. 2001 Aug-Dec; 24(1-3):107-29.
[Mol Neurobiol. 2001]Can Med Assoc J. 1982 Mar 15; 126(6):662-3.
[Can Med Assoc J. 1982]Neurotoxicol Teratol. 1995 Mar-Apr; 17(2):143-50.
[Neurotoxicol Teratol. 1995]Mini Rev Med Chem. 2002 Aug; 2(4):419-32.
[Mini Rev Med Chem. 2002]Carcinogenesis. 1999 Aug; 20(8):1411-6.
[Carcinogenesis. 1999]Brain Res. 2005 Jul 19; 1050(1-2):130-7.
[Brain Res. 2005]Neurosci Res. 2006 Sep; 56(1):103-10.
[Neurosci Res. 2006]Am J Physiol Regul Integr Comp Physiol. 2001 Nov; 281(5):R1343-60.
[Am J Physiol Regul Integr Comp Physiol. 2001]J Biol Chem. 2006 May 26; 281(21):14663-9.
[J Biol Chem. 2006]Brain Res Bull. 2008 Mar 28; 75(5):598-609.
[Brain Res Bull. 2008]Genome Biol. 2007; 8(1):R14.
[Genome Biol. 2007]Brain Res Bull. 2008 Mar 28; 75(5):598-609.
[Brain Res Bull. 2008]Neurotoxicol Teratol. 1995 Mar-Apr; 17(2):143-50.
[Neurotoxicol Teratol. 1995]Proc Natl Acad Sci U S A. 1997 Apr 15; 94(8):4103-8.
[Proc Natl Acad Sci U S A. 1997]Brain Res Bull. 2008 Mar 28; 75(5):598-609.
[Brain Res Bull. 2008]FASEB J. 2008 May; 22(5):1491-501.
[FASEB J. 2008]Brain Res. 2000 Aug 25; 874(2):123-30.
[Brain Res. 2000]Brain Res Bull. 2008 Mar 28; 75(5):598-609.
[Brain Res Bull. 2008]Anal Biochem. 2005 Aug 15; 343(2):203-11.
[Anal Biochem. 2005]Brain Res Bull. 2008 Mar 28; 75(5):598-609.
[Brain Res Bull. 2008]Brain Res Bull. 2008 Mar 28; 75(5):598-609.
[Brain Res Bull. 2008]Mini Rev Med Chem. 2002 Aug; 2(4):419-32.
[Mini Rev Med Chem. 2002]Brain Res. 1992 Oct 16; 593(2):209-14.
[Brain Res. 1992]Mini Rev Med Chem. 2002 Aug; 2(4):419-32.
[Mini Rev Med Chem. 2002]Neuropharmacology. 2008 Feb; 54(2):454-63.
[Neuropharmacology. 2008]Brain Res Bull. 2008 Mar 28; 75(5):598-609.
[Brain Res Bull. 2008]Neuroscience. 2004; 125(2):317-27.
[Neuroscience. 2004]Brain Res. 2008 Feb 8; 1193():153-61.
[Brain Res. 2008]J Neurochem. 2002 Jun; 81(5):1028-34.
[J Neurochem. 2002]FASEB J. 2008 May; 22(5):1491-501.
[FASEB J. 2008]Brain Res Bull. 2008 Mar 28; 75(5):598-609.
[Brain Res Bull. 2008]J Biol Chem. 2006 May 26; 281(21):14663-9.
[J Biol Chem. 2006]Proc Natl Acad Sci U S A. 2001 Jan 30; 98(3):1294-9.
[Proc Natl Acad Sci U S A. 2001]Brain Res. 2005 Jul 19; 1050(1-2):130-7.
[Brain Res. 2005]Brain Res Bull. 2008 Mar 28; 75(5):598-609.
[Brain Res Bull. 2008]Brain Res. 2004 Oct 22; 1024(1-2):59-76.
[Brain Res. 2004]Neuropharmacology. 2008 Feb; 54(2):454-63.
[Neuropharmacology. 2008]Brain Res Bull. 2008 Mar 28; 75(5):598-609.
[Brain Res Bull. 2008]